This Article  • References  • Full text PDF  • Correction  • Reply to article  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

Peter Williamson, MD, DPsY, FRCPC
London Psychiatric Hospital 850 Highbury Ave London, Ontario, Canada N6A 4H1

Dick Drost, PhD; Jeff Stanley, MSc; Thomas Carr, MD; Sandra Morrison, PhD; Harold Merskey, DM
London, Ontario

Arch Gen Psychiatry. 1991;48(6):578.

	Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

To the Editor.—

We are most interested in the article by Pettegrew et al¹ in this issue of the ARCHIVES. The authors report significantly reduced levels of phosphomonoesters (PMEs) and significantly increased levels of phosphodiesters (PDEs) in first-episode, nevertreated schizophrenic patients compared with normal matched control subjects. These findings could indicate decreased synthesis and/or increased breakdown of membrane phospholipids in schizophrenia.

We wish to report some preliminary results of localized phosphorus 31 (³¹P) magnetic resonance (MR) spectroscopy in chronic schizophrenic patients and normal control subjects.

Patients and Methods.—

Ten schizophrenic patients (nine men, one woman) between ages 33 and 54 years (mean± SD, 38.7±6.0 years) participated in the study. All were outpatients receiving an average chlorpromazine hydrochloride equivalent dose of 660 ± 436 mg. The diagnosis of schizophrenia was confirmed by a psychiatrist (P.W.) using the Structured Clinical Interview for DSMIII-R.² Length of illness was estimated . . . [Full Text PDF of this Article]

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?